Several additives have been combined with local anaesthetics for intravenous regional anaesthesia to improve block quality, analgesia and to decrease tourniquet pain. Magnesium sulphate is one potential additive. This prospective, randomised, double-blinded study was conducted in 30 ASA physical status I or II patients undergoing upper limb surgery under tourniquet. In group L, patients received intravenous regional anaesthesia with lignocaine alone (9 ml of 2% lignocaine diluted with normal saline to total volume of 36 ml). Patients in group M received intravenous regional anaesthesia with lignocaine plus magnesium sulphate (6 ml of 25% magnesium sulphate plus 9 ml of 2% lignocaine diluted with normal saline to total volume of 36 ml). Assessment was by observing the response to injection of drug; sensory and motor block and tourniquet pain.
Intravenous regional anaesthesia (IVRA) (Bier's block) is one of the simplest forms of regional anaesthesia and has been practised for almost 100 years. Intravenous regional anaesthesia is a simple, safe and reliable technique for providing anaesthesia, as well as a bloodless field, during limb surgery. However, its use is limited by the fact that it can only be used for surgery of short duration. Other limitations include tourniquet pain, poor muscle relaxation and its inability to provide postoperative analgesia. There is also a risk of systemic toxicity on tourniquet deflation.
To improve block quality, prolong post-deflation analgesia and decrease tourniquet pain, different additives have been combined with local anaesthetics. Magnesium sulphate is one potential additive that has been shown to have antinociceptive effects and to decrease perioperative analgesic requirements in other settings 1 .
Thus we designed this prospective, randomised, double-blinded study to assess the quality of anaesthesia using magnesium sulphate as an adjuvant to lignocaine for IVRA for upper limb surgery.
MATERIALS AND METHODS
After Institutional Review Board and ethical committee approval, this prospective, randomised, double-blinded study was conducted in 30 ASA physical status I or II adult patients of either gender in the age group of 18 to 60 years and scheduled to undergo upper limb surgery under tourniquet.
Patients with peripheral vascular disease, coronary artery disease, sickle cell anaemia, history of allergy to any drug or impaired kidney function were excluded from the study.
Informed written consent (including consent for the study drug) was obtained from all patients. Laboratory investigations included blood urea, serum creatinine and serum electrolytes (sodium and potassium).
In the operating room, routine monitors were attached and the baseline pulse rate, systolic blood pressure, diastolic blood pressure and oxygen saturation (SpO 2 ) were recorded. Two intravenous cannulae were placed -one (20 G) in a vein on the dorsum of the hand of the operative limb and the other (18 G) in the opposite hand for crystalloid infusion. The patient was given intravenous midazolam 0.03 mg/kg. The tourniquet equipment was tested for leaks before each surgery. Resuscitation drugs were kept ready. The operative arm was elevated for two minutes and exsanguinated with an Esmarch bandage. A double-cuffed pneumatic tourniquet was then placed around the upper arm. The proximal cuff was inflated to 100 mmHg above the systolic blood pressure. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse and a loss of the pulse oximetry tracing in the ipsilateral index finger. Patients were then randomly allocated (using a computer-generated randomised list) into two groups of 15. An independent anaesthesiologist, not involved in the observation, prepared identical syringes containing each drug as follows:
Group L (n=15): For patients who were to receive IVRA with lignocaine alone, 9 ml of 2% lignocaine (preservative-free) was diluted with normal saline to make a total volume of 36 ml and the resultant concentration of lignocaine to be 0.5%.
Group M (n=15): For patients who were to receive IVRA with lignocaine plus magnesium sulphate, 6 ml of 25% magnesium sulphate (12.4 mmol) plus 9 ml of 2% lignocaine (preservative-free) were diluted with normal saline to make a total volume of 36 ml and the resultant concentration of lignocaine to be 0.5%.
The solution was injected over 90 seconds by an anaesthesiologist blinded to the injected drugs. After sensory and motor block onset, the operative tourniquet (distal cuff) was inflated to 100 mmHg above the systolic blood pressure and the proximal tourniquet was released. The occurrence of bradycardia (25% decrease from baseline), hypotension (25% decrease from baseline) and decreased SpO 2 (<96%) were noted and managed appropriately. The tourniquet was not deflated before 30 minutes and was not inflated for over two hours. At the end of surgery, the tourniquet was deflated by a cyclic deflation technique.
Outcome measures included assessment of sensory block (onset and recovery time), motor block (onset and recovery time) and tourniquet pain.
Response to injection of drug was assessed by the following numerical scale: 0=none: negative response to questioning. • 1=mild: pain reported in response to questioning • only, without any behavioural signs. 2=moderate: pain reported in response to • questioning and accompanied by a behavioural sign or pain reported spontaneously without questioning. 3=severe: strong vocal response or response • accompanied by facial grimacing, arm withdrawal or tears. Sensory block was assessed by pinprick with a 22 G, short-bevelled needle every 30 seconds. Patient response was evaluated in the dermatomal sensory distribution of the medial and lateral antebrachial cutaneous, ulnar, median and radial nerves. Onset of sensory block was defined as the time elapsed from the injection of the drug to sensory block achieved in all dermatomes. Sensory recovery time (the time elapsed from tourniquet deflation to recovery of sensation in all dermatomes, determined by pinprick test) was noted.
Motor function was assessed by asking the subject to flex and extend his or her wrist and fingers. Complete motor block was noted when no voluntary movement was possible. Onset of motor block was defined as the time elapsed from injection of the study drug to complete motor block. Motor block recovery time (the time elapsed from tourniquet deflation until movement of fingers) was noted.
Assessment of tourniquet pain score was done on the basis of the visual analogue scale (VAS) (0=no pain and 10=worst pain imaginable). when tourniquet pain was >3 on the VAS, patients were given fentanyl 1 µg/kg intravenously and the total administered dose and requirement time was noted.
Postoperatively, patients received 1.5 mg/kg diclofenac intramuscularly when VAS >3. Nausea, vomiting, skin rash, tachycardia, bradycardia, hypotension, hypertension, headache, dizziness, tinnitus, hypoxaemia, sedation and other sideeffects were noted if encountered within 24 hours postoperatively.
A reduction on the tourniquet pain score (VAS) of 15% among two groups was considered clinically relevant. On the basis of this, a sample size of 15 patients was found to be sufficient to allow a type 1 error of a=0.05 with a power of 0.8. Student's t-tests were used for evaluation of the demographic data, time of onset and recovery of sensory and motor block, duration of analgesia and intraoperative analgesic use. The Mann-whitney u-test was used for comparison of intraoperative VAS scores. A P value of <0.05 was considered significant.
RESuLTS
The two study groups were comparable with regard to age, gender, weight and ASA physical status ( Table 1 ).
The nature of the surgery, though comparable between the two groups, was quite variable within the groups ( Table 2 ). The duration of surgery and the total tourniquet time were comparable in groups L and M.
Of the patients in group M, 66.7% reported moderate to severe pain while the study drug was being injected as compared to 20% in group L (P=0.011). Two patients (13.3%) in group L reported severe pain on injection of drug.
Sensory and motor block onset was statistically significantly faster in group M. In five patients in group L and three patients in group M, motor blockade was partial. Surgery was possible in these patients as sensory blockade was present and due to the nature of the surgical procedure, motor blockade was not required. The difference in motor block recovery times between the two groups was not different (P=0.2, Table 3 ). In a total of three patients, recovery of sensory and motor block could not be assessed, as they required general anaesthesia (see below).
There was a statistically significant difference in VAS for tourniquet pain at 10 and 30 minutes after tourniquet inflation. VAS was lower in group M (Table 4 ).
Thirteen out of 15 patients in Group L required fentanyl, while only 10 out of 15 in Group M required fentanyl. The mean duration at which fentanyl was required in group L was 29.6 minutes and 51.2 minutes in group M. Total average dose of fentanyl given was similar between the groups (P=0.875).
Three patients in our study had to be given general anaesthesia (two in group L and one in group M). ORIF=open reduction and internal fixation. There was no statistical difference between groups for pulse rate, mean blood pressure or SpO 2 at any time.
One patient in each of groups L and M experienced bradycardia during tourniquet deflation that was successfully treated with a single dose of intravenous atropine. One patient in group M had bradycardia during inflation of tourniquet. One patient in group M had a decrease in SpO 2 to 94% and was managed conservatively with oxygen supplementation by face mask. No other significant side-effect was observed.
DISCuSSION
Our study showed that with the addition of magnesium to IVRA, the onset of the sensory and motor block are hastened. The tourniquet pain is decreased, thus reducing the requirement of analgesic supplement intraoperatively. However, there is a high incidence of injection pain if magnesium is added.
The speed of sensory and motor block onset was significantly improved on adding magnesium in our study. Though there was some variation in the mean onset of sensory and motor block compared with earlier reports, such variations (ranging from four to 14 minutes for sensory block onset and from five to 15 minutes for motor block onset) are well documented in the literature 2, 3 .
Four cases in group L and three in group M did not achieve complete motor block. Motor weakness did occur in all cases, but a slight movement of fingers persisted in these patients. Peng et al reported that out of 20 patients who received 0.5% lignocaine for IVRA only three developed complete motor block 4 .
The mean sensory and motor recovery time in our study were also prolonged in the magnesium group. Like the block onset time, the block recovery time has also been shown to be extremely variable in the different studies using 0.5% lignocaine 3, 5 .
A significant improvement in intraoperative VAS scores was seen in our study at 10 and 30 minutes after tourniquet inflation in group M. The lower VAS at 10 minutes may probably be due to early onset of sensory block in group M, but lower VAS at the later time indicates a beneficial role of magnesium sulphate in reducing the tourniquet pain.
we used a total of 36 ml solution for IVRA, which was based on approximate average weight in our general population and to achieve a lignocaine concentration of 0.5%. The conventional volume mentioned in the literature for IVRA is up to 40 to 50 ml.
The need for fentanyl supplementation in the two groups was consistent with Turan et al, who observed a prolongation in the fentanyl requirement time from 22 minutes to 35 minutes on adding magnesium 6 . All 15 patients in their control group received fentanyl, while only three patients of 15 in their study group were given fentanyl.
Although a greater number of patients in group M in our study required fentanyl administration as compared to a previous study 1 , this might be due to the fact that the average tourniquet time was longer in our study.
No serious side-effects were observed in either group.
The mechanism of the analgesic effect of magnesium is not clear, but interference with calcium channels and N-methyl-D-aspartate receptors seems to play an important role 1, 7 . The pneumatic tourniquet causes ischaemia which distorts nerve penetration of the local anaesthetic by oxidative stress 6 . Magnesium has an endothelium-derived nitric oxide-induced vasodilatory effect and protects vascular endothelium from ischaemia/reperfusionmediated endothelial dysfunction 6 .
The drugs administered in our study were warmed to body temperature before injection. It is reported in the literature that the veins are cold-sensitive and a cold solution may provoke venoconstriction 8 . This may possibly raise the intravascular pressure of the secluded limb and thus increase the possibility of drug leakage from the tourniquet.
The exact aetiology of pain on intravenous injection of magnesium sulphate is unknown but has been attributed to acidity of the solution 7, 9 . Tramer et al used magnesium in the Bier's block for treatment of chronic limb pain and reported a superficial burning or a deep aching (localised in the muscles or the bones) on injection in 52% of the patients 7 . Agarwal et al reported an incidence of 31% pain on injection of magnesium used as pre-treatment for reducing pain of propofol adminstration 10 . Out of the patients who had reported pain on injection of the drug in group M in our study, most indicated that it was transient and that it subsided without treatment in a few seconds. Two patients in group L complained of severe pain on drug injection. Both these patients were operated on for Galeazzi fracture. We could not find a satisfactory explanation for the pain experienced by them on injection of lignocaine, although pain on injection of local anaesthetic solution in IVRA has been reported previously with prilocaine and chloroprocaine 11, 12 and alkalinisation of the solution has been found to be effective in reducing the pain of injection of prilocaine 11 .
To fully explore the results concerning the injection pain due to magnesium, faster onset of sensory and motor block and decreased tourniquet pain with magnesium sulphate added as an adjuvant to lignocaine in IVRA, further studies including a large number of subjects are needed.
Thus our study showed that magnesium sulphate added as an adjuvant to lignocaine for IVRA hastens the onset of sensory and motor block and decreases tourniquet pain (improved VAS scores and increased duration to the need for additional analgesia) without causing any serious side-effects. However, transient pain on injection if magnesium sulphate is added is common.
